GlassScriptPhysician profile
Mara R Holton
NPI 1275677874
$13,310.47
in general payments reported to CMS, 2019-2025
35 companies · $4,241 in 2025
The $4,241 reported for 2025 was more than what 89% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $64.20 · 2021: $387 · 2022: $3,361 · 2023: $2,249 · 2024: $2,152 · 2025: $4,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,659 · Consulting Fee: $3,420 · Honoraria: $1,000 · Travel and Lodging: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,659.39 |
| Consulting Fee | $3,420.00 |
| Honoraria | $1,000.00 |
| Travel and Lodging | $563.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $3,660.90 | 2022-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $3,471.00 | 2019-2025 | |
| Verity Pharmaceuticals INC. | $1,000.00 | 2024 | |
| Axonics, INC. | $794.11 | 2021-2024 | Axonics |
| Urogen Pharma, INC. | $597.32 | 2020-2025 | Jelmyto |
| Valencia Technologies Corporation | $593.21 | 2023 | Ecoin Device Kit |
| Dendreon Pharmaceuticals LLC | $457.99 | 2019-2025 | Provenge |
| Boston Scientific Corporation | $403.32 | 2019-2025 | Axonics, Rezum Generator, Advantage System |
| Abbvie INC. | $293.42 | 2019-2024 | |
| Astellas Pharma US INC | $290.68 | 2019-2025 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $220.10 | 2021-2024 | Erleada, Akeega |
| Allergan, INC. | $165.11 | 2019 | |
| Ferring Pharmaceuticals INC. | $147.26 | 2025 | Adstiladrin |
| Pfizer INC. | $146.96 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $144.64 | 2023 | Prolaris |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $136.81 | 2023 | Illuccix |
| Sumitomo Pharma America, INC. | $119.97 | 2024-2025 | Orgovyx, Gemtesa |
| Baxter Healthcare | $94.53 | 2024 | Tisseel |
| Immunitybio, INC. | $90.75 | 2025 | |
| Coloplast Corp | $67.66 | 2023 | Titan |
| Olympus America INC. | $61.56 | 2023-2025 | Itind System, Tecoflex |
| Stryker Corporation | $52.19 | 2019 | |
| Myovant Sciences INC. | $38.33 | 2022 | |
| Endo Pharmaceuticals INC. | $34.43 | 2022 | |
| Tempus Ai, INC | $29.35 | 2024 | Xt Cdx |
| Tolmar, INC. | $25.49 | 2024 | |
| Progenics Pharmaceuticals, INC. | $24.42 | 2023 | Pylarify |
| Tolmar Pharmaceuticals, INC. | $21.91 | 2021 | |
| Laborie Medical Technologies Corp. | $21.14 | 2020 | |
| Medtronic, INC. | $19.18 | 2022 | |
| Teleflex LLC | $18.95 | 2023 | Urolift |
| Amgen INC. | $18.69 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.07 | 2025 | |
| Shire North American Group INC | $16.29 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $15.73 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mara Holton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.